CN107661422B

CN107661422B - Traditional Chinese medicine composition for preventing and treating coronary heart disease and preparation method thereof

Info

Publication number: CN107661422B
Application number: CN201710983855.4A
Authority: CN
Inventors: 杨旭杰; 裴晓华
Original assignee: Beijing University Of Chinese Medicine Third Affiliated Hospital; Hebei University of Chinese Medicine
Current assignee: Beijing University Of Chinese Medicine Third Affiliated Hospital; Hebei University of Chinese Medicine
Priority date: 2017-10-20
Filing date: 2017-10-20
Publication date: 2020-11-10
Anticipated expiration: 2037-10-20
Also published as: CN107661422A

Abstract

The invention discloses a traditional Chinese medicine composition for preventing and treating coronary heart disease, which is mainly prepared from eupatorium japonicum, bighead atractylodes rhizome, ligusticum wallichii, poria cocos, rhizoma corydalis, immature bitter orange, cassia twig, apocynum venetum and other medicines according to a certain weight ratio. It can be prepared into any common oral administration dosage form. The whole formula has the effects of nourishing blood and calming heart, strengthening spleen and tonifying qi, activating blood and dissolving stasis, and promoting qi circulation and diuresis, and has definite curative effect on preventing and treating coronary heart disease and complications thereof.

Description

Traditional Chinese medicine composition for preventing and treating coronary heart disease and preparation method thereof

Technical Field

The invention belongs to the field of traditional Chinese medicines for preventing and treating cardiovascular and cerebrovascular diseases.

Background

Coronary heart disease is the short term for coronary atherosclerotic heart disease and is the clinical syndrome caused by coronary insufficiency, acute and transient myocardial ischemia and anoxia.

The disease is caused by lipid metabolism disorder, lipid in blood is overoxidized and deposited under the artery intima to form a lipid plaque, so that the originally smooth intima becomes rough and the soft tube wall becomes rigid; on the basis, the broken platelets are also aggregated and adhered to the surface of the heart, which leads to the blockage or occlusion of coronary arteries over time and induces myocardial ischemia and hypoxia, so the heart disease is also called ischemic heart disease. Coronary heart disease is a common disease which endangers the health of middle-aged and elderly people and shows a tendency of youthfulness.

Currently, three major treatment routes internationally recognized include drug therapy, interventional therapy and surgical therapy. The surgical therapy mainly refers to coronary artery bypass surgery, which can improve the ischemic state of the myocardium but can not save the myocardial cells necrotized by ischemia, so that the heart failure cannot be resisted; the interventional therapy is the placement of an internal stent of a coronary artery, the stent implantation can effectively solve the stenosis and the occlusion of the coronary artery, but the implantation of a foreign body stent easily causes reactions such as rejection, allergy and the like, increases the chance of infection, and easily causes vascular intimal injury, platelet aggregation, thrombus formation and restenosis; interventional and surgical treatments do not prevent stenosis of other coronary arteries in patients and thus do not cure coronary heart disease; the drug therapy is the basis of various treatment methods of coronary heart disease, various revascularization operations can be applied on the premise of giving reasonable drug therapy, and patients can benefit to the maximum extent only by applying various drug therapies after operation.

The therapeutic principle of chemical medicine is to improve coronary artery blood supply and reduce myocardial oxygen consumption, and at the same time, it can be used for curing atherosclerosis, and its therapeutic medicine can be divided into three categories.

The first type is nitrate formulations. The main functions are expanding coronary artery, reducing resistance, reducing load around heart and oxygen demand of cardiac muscle, and further relieving angina pectoris. The common preparations include nitroglycerin, isoamyl nitrite, penta-tetranitrate, isosorbide dinitrate, etc.

The second class is receptor blockers. Blocking the stimulation of sympathomimetic amines on heart rate and heart contractility, slowing down heart rate, reducing blood pressure, reducing heart muscle contractility and oxygen consumption, and further relieving the attack of angina pectoris. The most commonly used formulations are atenolol, bisoprolol, metoprolol, esmolol, propranolol, and the like.

The third class is calcium channel blockers. The main functions are to inhibit calcium ions from entering cells and also inhibit the calcium ions in the coupling of excitation and contraction of myocardial cells, thereby inhibiting myocardial contraction, reducing myocardial oxygen consumption and improving the blood supply of subendocardial myocardium. The common preparations comprise nifedipine, nimodipine, amlodipine, diltiazem and the like.

The above chemicals are basically able to control the acute phase of the disease, but do not completely solve the problem of coronary stenosis and the symptoms of atherosclerosis. The long-term taking of the health-care food not only can cause the tolerance of the organism and increase the burden of the liver and the kidney, but also can stimulate the gastrointestinal tract and bring different degrees of damage to various tissues and organs of the human body.

Coronary heart disease belongs to the categories of ' obstruction of qi in the chest ', ' true heart pain ', ' syncope heart pain ' and the like in traditional Chinese medicine, the records of ' vital energy is necessary to be deficient and can not reach blood vessels, the blood vessels are free of air and must stay as stasis ' exist in doctor Ling correction ', heart vessel obstruction becomes a well-known main pathogenesis, and therefore, the blood circulation activation and the blood stasis removal become the fundamental method for treating obstruction of qi in the chest and the heart pain. The commonly used Chinese patent medicines comprise coronary heart disease salvia dropping pills, coronary heart disease calming oral liquid, coronary heart disease calming tablets, coronary heart disease storax capsules, coronary heart disease calming tablets, compound salvia tablets, heart and brain clearing soft capsules and the like. These patent drugs largely relieve the pain of patients with coronary heart disease, but the prevention and treatment requirements of the disease are not met due to the relative singleness of the treatment rules and the expansion of the population of patients with coronary heart disease.

The disease is mostly caused by deficiency of origin and excess of superficiality, the deficiency of origin is mainly caused by qi deficiency, the excess of superficiality is caused by heart vessel stasis, the deficiency of qi is not caused by blood circulation, the blood circulation is not smooth, the heart vessel is blocked, the heart fails to nourish, the disease course is long, the internal stagnation of blood stasis and the deficiency of qi and blood are formed.

The disease is closely related to the whole body, has complex and various pathogenic factors, and can be induced by old and weak body, deficiency of kidney qi, thick taste of ointment, damage to spleen and stomach, internal injury due to seven emotions, qi stagnation and blood stasis, and tiredness. The imbalance of qi and blood functions of zang-fu organs and meridians breaks down the balance of yin, yang and qi. Is the intrinsic cause of the disease. The pathogenesis of the chronic bronchitis comprises the symptoms of chest yang deficiency, qi deficiency and blood stasis, qi stagnation and blood stasis, phlegm obstruction of heart vessels, yin cold stagnation, qi-yin deficiency, heart-kidney yin deficiency and the like. According to traditional Chinese medicine, the heart, spleen and kidney deficiency are the primary factors, and qi stagnation, blood stasis and phlegm turbidity are the secondary factors, and are mostly presented by the combination of vital qi deficiency, pathogenic factors excess, deficiency and excess.

Under the guidance of holistic concept and treatment based on syndrome differentiation, the traditional Chinese medicine adopts a method combining syndrome differentiation and disease differentiation to prevent and treat coronary heart disease, and treats both principal and secondary aspects of diseases through two major principles of tonifying and dredging.

Disclosure of Invention

The inventor is engaged in clinical work of coronary heart disease for many years, and through screening of diagnosis and treatment medicines for a plurality of patients with coronary heart disease and animal experiment verification, the invention is completed by determining the traditional Chinese medicine composition with definite curative effect.

The invention aims to provide a traditional Chinese medicine composition with definite curative effect for preventing and treating coronary heart disease.

The invention also aims to provide a preparation method of the traditional Chinese medicine composition.

The medicine of the invention is prepared by 11 traditional Chinese medicines of eupatorium japonicum, bighead atractylodes rhizome, ligusticum wallichii, immature bitter orange, rhizoma corydalis, poria cocos, cassia twig, buckeye, apocynum venetum, rhizoma acori graminei and honey-fried licorice root.

Herba Lycopi (Eupatorii Japonici Thunb) is stem and leaf of Dioscorea Opposita Linn of Labiatae. Pungent and bitter in flavor, slightly warm in nature, entering liver and bladder meridians. Has effects in promoting blood circulation, dispelling blood stasis, inducing diuresis, and relieving swelling; the Chinese medicinal composition is mainly used for treating blood stasis amenorrhea, dysmenorrhea, abdominal mass, postpartum abdominal stasis and pain, edema of the body and the face, traumatic injury, edema and the like in clinic.

The time treasure is recorded as that the eupatorium is fragrant and warm, pungent and scattered, the yang of yin is also the yin of foot, and the medicine of jueyin meridian. The spleen prefers to be aromatic, the liver prefers to be pungent and disperse, and the spleen qi is comfortable, so the triple energizer can promote diuresis and regulate qi; when liver qi stagnation disperses, the pathogenic factors will be released due to the prevailing ying-wei system. The orchid herb moves in the air passage, so the orchid herb can promote diuresis, eliminate phlegm and nodule, kill parasitic cup and expel evil and is a good drug for treating thirst; herba Lycopi is the essential herb for women because it can remove blood, so it is indicated for edema, abscess, blood stasis and mass.

It is recorded in Benjing to be mainly used for treating internal hemorrhage of breast and women, apoplexy, edema of the abdomen, edema of the body, the face and the limbs, edema of the bone joints, incised wound, carbuncle, swelling, sore and pus. The book of Olympic records considers that the medicine has the effects of dredging nine orifices, benefiting joints, nourishing blood and qi, breaking persistent blood, eliminating mass, dredging small intestine, growing muscles, eliminating blood stasis, and treating nosebleed, hematemesis, headache, eye pain, female marasmus and yellow complexion of husband. The effective components of herba Lycopi include volatile oil, glucoside, tannin and resin, and flavone, phenol, amino acid, organic acid, saponin, and various saccharides. Modern pharmacological research proves that the herba lycopi has the following pharmacological actions: (1) and (4) anticoagulation. The herba lycopi decoction can prolong the blood coagulation time of a mouse and reduce the quality of arteriovenous thrombus of the rat; prolonging the calcium-recovering and blood-clotting time, prothrombin time, kaolin prothrombin time and thrombin time of rabbit plasma, and increasing the antithrombin activity of the plasma; the decoction can inhibit platelet aggregation in rabbit. (2) Improve the rheological property of blood. The herba lycopi water decoction can reduce the specific viscosity of whole blood, the specific viscosity of blood plasma, the reduction viscosity of whole blood and the hematocrit of the rabbit, and shorten the electrophoresis time of red blood cells; can improve the erythrocyte deformability of a blood stasis model rat caused by the intravenous injection of the high-molecular dextran, inhibit the aggregation of erythrocytes and increase the fluidity of erythrocyte membranes. (3) Improving microcirculation. Herba Lycopi decoction can reduce blood viscosity, inhibit accumulation of erythrocyte and platelet, improve microcirculation and exert antibacterial effect; the method increases the number of open capillaries with normal rabbit bulbar conjunctiva function, improves the micro-blood flow state of a rabbit microcirculation disturbance model caused by high-molecular dextran, reduces granular flow, broken flow and flocculent flow, and obviously increases the intersection point count and the full visual field in the functional capillaries.

Herba lycopi has double effects of activating blood and promoting diuresis, is a common medicament for clinically preventing and treating coronary heart disease, hyperlipidemia and atherosclerosis, and is used as a monarch medicament in the formula.

Atractylodis rhizoma (Atractylodes macrocephala) is a plant of Atractylodes of Compositae, and is used as medicine. Bitter and sweet in taste, warm in nature, entering spleen and stomach meridians. Has the effects of strengthening spleen, replenishing qi, eliminating dampness, inducing diuresis, suppressing sweating, and preventing miscarriage. It is used clinically to prevent and treat diseases such as spleen deficiency, anorexia, abdominal distention, diarrhea, phlegm and fluid retention, dizziness, palpitation, edema, spontaneous perspiration, and threatened abortion. Modern pharmacological studies have shown that the intra-dolol of Atractylodis rhizoma can reduce the contractility of right atrial muscle and slow down its heart rate, and can reduce the positive stair-stepping effect of left atrial muscle.

The white atractylodes rhizome has the special efficacy of strengthening spleen and tonifying qi, the spleen is positioned in the middle energizer to irrigate the four sides, the spleen raises the clear and lowers the turbid, the spleen qi is healthy and transported, the food is formed into minute and fine nutrition limbs and bones, the dregs are discharged out of the body, no water, damp phlegm and blood stasis are left in the channels and collaterals, and the coronary atherosclerosis is restrained from the source. The using amount of the bighead atractylodes rhizome in the invention is slightly less than that of herba lycopi, and the bighead atractylodes rhizome serves as a ministerial drug in the whole formula.

Rhizoma Ligustici Chuanxiong (Ligusticum chuanxiong Hort) is dried rhizome of plant of Umbelliferae. Pungent flavor and warm nature. It enters liver, gallbladder and pericardium meridians. Growing in a mild climatic environment. It is commonly used for promoting blood circulation and activating qi-flowing, dispelling pathogenic wind and relieving pain, rhizoma Ligustici Chuanxiong is pungent, warm, fragrant and dry, and can disperse and ascend to the vertex; it enters the blood system and goes down to reach the blood sea. Promoting blood circulation and removing blood stasis, it is suitable for various diseases due to blood stasis. Chuan Xiong is known as qi-tonifying herb in blood because of its actions of dispersing pungent qi, resolving stagnation, promoting blood circulation, moving qi, etc.

The traditional Chinese medicine considers that the main cause of coronary heart disease, angina, myocardial infarction and atherosclerosis is unsmooth blood circulation. Modern pharmacological research proves that the ligusticum wallichii activates blood vessels by improving the cardiovascular and cerebrovascular functions, the physical and chemical properties of blood, the functions of platelets and a blood coagulation system, microcirculation and other physiological functions, and removes stasis by resisting myocardial ischemia and cerebral ischemia, inhibiting platelet aggregation, resisting coagulation and resisting thrombosis.

The main components of rhizoma Ligustici Chuanxiong include ligustrazine, ferulic acid, alkaloid, chuanxiong element, phenolic substance, organic acid, phthalide lactone, etc. Ligustrazine is a main effective component, and is mainly applied to ischemic cardiovascular and cerebrovascular diseases; ferulic acid is the main active ingredient for preventing and treating cardiovascular diseases, can improve blood circulation, prevent coagulation and inhibit platelet aggregation, play a role in resisting thrombus obviously, and inhibit vascular endothelial cell VsMC hyperplasia induced by angiotensin II by inhibiting extracellular regulation protein kinase and stress activation protein kinase; has the effects of inhibiting macrophage activation, inhibiting arachidonic acid metabolism, antagonizing histamine, reducing vascular permeability, resisting oxidation, scavenging free radicals, etc.

The ligusticum wallichii is taken as a ministerial drug and assists a monarch drug, namely the herba lycopi, in strengthening the effects of activating blood and removing stasis.

Corydalis tuber (Corydalis ambigua), also known as Corydalis tuber and Corydalis tuber, is a perennial herb of Corydalis of Papaveraceae, and is commonly called Zhe eight-flavor with Atractylodes macrocephala, peony, fritillaria, etc., as a bulk of commonly used Chinese medicines. Rhizoma corydalis is recorded in Kai Bao Ben Cao, warm in nature, pungent and bitter in flavor, enters heart, spleen, liver and lung, is a wonderful product for activating blood circulation to dissipate blood stasis, promoting qi circulation to alleviate pain, and is especially known to have the effect of relieving pain. Li Shizhen induces that rhizoma corydalis has four main effects of promoting blood circulation, activating qi, relieving pain and removing urine from Ben Cao gang mu, and Chong rhizoma corydalis is specially used for treating pain in upper and lower parts of the whole body because it can promote qi stagnation in blood and qi stagnation in blood. Corydalis tuber contains various alkaloids: d-corydaline, dl-tetrahydropalmatine, protopine, l-tetrahydrocoptisine, d 1-tetrahydrocoptisine, coptisine, etc.

Poria (also known as Yuling, Fu Ling, Wanling Gui, Fu Tu. Is dry sclerotium of Poria cocos (Schw.) wolf of Polyporaceae, usually parasitized on pine root, shaped like sweet potato, spherical, light brown or black brown outer skin, and pink or white inner part, and refined to obtain Poria cocos (Schw.) wolf or Poria cocos (Schw.) wolf; sweet and light taste, neutral in nature, entering heart, lung, spleen and kidney meridians, and having the effects of promoting diuresis, eliminating dampness, invigorating spleen and tranquilizing; mild property, eliminating dampness without damaging healthy qi; the aqueous extract can enhance myocardial contractility and accelerate heart rate; the main component of poria cocos extract can inhibit the permeability of capillary vessels and increase the intake of myocardial Rb; the tuckahoe water extract and the tuckahoe ethanol extract can obviously reduce the blood sugar of the rabbit. In the invention, the poria cocos assists the ministerial drug rhizoma atractylodis macrocephalae to play the effects of strengthening spleen, tonifying qi, promoting diuresis and excreting dampness, and assisting healthy qi to dispel damp turbidity.

Ramulus Cinnamomi (Cinnamomum cassiaPresl) is twig of Cinnamomum cassia Presl of Lauraceae, and has warm nature, pungent taste, and sweet taste, and has effects of warming channels and activating yang; comprises trans-cinnamic acid, coumarin, beta-sitosterol, protocatechuic acid, cinnamaldehyde and glucoside; the cinnamoylaldehyde can expand peripheral blood vessels, enhance blood circulation, remarkably increase coronary flow and improve coronary circulation; completely inhibiting the effect of thrombin in promoting fibrinogen to fibrin; the time for bovine thrombin to coagulate human fibrinogen is obviously prolonged, and the blood coagulation is resisted; the cassia twig distillate can inhibit the reduction of coronary blood flow and the release of myocardial cell lactate dehydrogenase and phosphocreatine kinase during myocardial ischemia reperfusion injury of rats, and plays a role in resisting lipid peroxidation, thereby protecting myocardial ischemia reperfusion injury. In the invention, the cassia twig plays the roles of warming and dredging heart vessels and inspiring heart yang.

Radix Glycyrrhizae Preparata (Radix Glycyrrhizae) is a honey-fried product of root and rhizome of Glycyrrhiza uralensis Fisch of Glycyrrhiza of Leguminosae, has sweet taste and neutral nature, and can enter spleen, stomach, heart and lung channels, and has effects of invigorating spleen-stomach, invigorating qi, and relieving spasm and pain. The effective components of the composition are triterpenes, flavonoids, a small amount of alkaloid, lignin, polysaccharide, trace elements and the like. Prepared licorice has excellent curative effect on arrhythmia caused by several reasons. The licorice total flavonoids are the main material basis of licorice antiarrhythmic, can antagonize arrhythmia caused by aconitine, ouabain and other medicines, protect myocardial contraction and have obvious myocardial ischemia resisting activity; radix Glycyrrhizae Preparata has good therapeutic effect on arrhythmia caused by ischemia reperfusion, low potassium and low magnesium, and can shorten BaCl₂The time for inducing arrhythmia of rats is obviously reduced, and the effect is enhanced along with the increase of the dosage; sodium glycyrrhetinate can obviously reduce animal blood fat, the contained 3-aromatic coumarin derivative GU-7 can inhibit platelet aggregation, and glycyrrhetinic acid has wide arrhythmia resisting effect and obvious effect on rapid and slow arrhythmia and various premature contractions. In the formula, the prepared licorice root not only plays a pharmacological role in preventing and treating cardiovascular diseases, but also is used as a Chinese medicament for harmonizing various medicaments of the whole formula.

Semen aesculi (Chinese buckeye seed) including semen perillae, semen rosae rugosae and pistachio nuts, which are seeds of aesculus chinensis of aesculaceae; sweet taste, warm nature, liver and stomach meridians entered, and has effects of dispersing stagnated liver qi, relieving epigastric distention and regulating stomach; mainly contains triterpenoid saponin and flavonoid compounds, can reduce blood fat, and can relieve angina pectoris by single Chinese medicinal tablet.

Rhizoma Acori Graminei (Acorus) is rhizome of Acorus gramineus Soland of Araceae, has warm nature and pungent taste, and has effects of inducing resuscitation, tranquilizing mind, eliminating dampness and regulating stomach; the rhizome contains volatile oil, and the main components are beta-asarone, acorus calamus ether, amino acid, organic acid and saccharide; the beta-asarone can expand the coronary vessels of the guinea pigs; asarone significantly reduced serum cholesterol in hypercholesterolemic mice; the water decoction can be used for resisting rabbit arrhythmia induced by epinephrine and barium chloride.

Apocynum venetum (Apocynum venetum) is a whole plant of Apocynaceae plant Apocynum venetum, is slightly cold in nature and light and astringent in taste, has the effects of calming the liver, clearing heat and promoting diuresis, and is an important traditional Chinese medicine for reducing blood pressure; the main ingredients comprise flavonoid glycoside, succinic acid, triacontanol, hyoscyami, glutamic acid and potassium chloride; the apocynum venetum extract water filtrate can reduce venous blood pressure of the anesthetized dog and slow down the heart rate of the anesthetized dog; the total cholesterol and triglyceride in serum of rat with hyperlipidaemia are obviously reduced; inhibiting thrombin-induced platelet aggregation; the apocynum venetum flavonoid glycoside has obvious expansion effect on blood vessels of in-vitro rabbit ears, so that the outflow volume of perfusate is obviously increased.

Fructus Aurantii Immaturus (Fructus Aurantii Immaturus) is dry young fruit of Citrus aurantium and cultivar of Rutaceae or Citrus sinensis, has bitter, pungent and acidic taste, warm nature, and is effective in invigorating spleen, stomach and large intestine, and has effects of relieving flatulence, resolving food stagnation, eliminating phlegm and relieving oppression; the book of the patent of pharmacy & ltYi of pharmacy & gt is characterized in that: zhi Shi is used for treating excess stomach and resolving hard mass, so it is mainly indicated for blood system in Zhongwan, treating fullness and distention between umbilicus and abdomen, eliminating phlegm nodule, removing stagnant water, dispelling indigestion, breaking and coagulating chest, relaxing bowels and block, but not for all. For itching skin, it is unable to nourish the skin surface due to blood stagnation in the middle, and for poor appetite, it is also pungent, dispersing and purging to remove the pathogenic wind and dampness due to spleen stagnation. It is the most important herb for qi in blood. "

The dosage of each traditional Chinese medicine in the invention is obtained by long-term clinical and animal experiments of the inventor. The components have better curative effect within the following weight ranges:

24-32 parts of herba lycopi, 14-22 parts of bighead atractylodes rhizome, 14-22 parts of ligusticum wallichii, 14-22 parts of corydalis tuber, 8-16 parts of poria cocos, 8-16 parts of cassia twig, 8-16 parts of honey-fried licorice root, 6-14 parts of buckeye, 6-14 parts of apocynum venetum, 6-14 parts of rhizoma acori graminei and 4-8 parts of immature bitter orange.

The further mixture ratio is as follows: 26-30 parts of herba lycopi, 16-20 parts of bighead atractylodes rhizome, 16-20 parts of ligusticum wallichii, 16-20 parts of rhizoma corydalis, 10-14 parts of poria cocos, 10-14 parts of cassia twig, 10-14 parts of honey-fried licorice root, 8-12 parts of buckeye, 8-12 parts of apocynum venetum, 8-12 parts of rhizoma acori graminei and 5-7 parts of immature bitter orange.

Preferably: 28 parts of herba lycopi, 18 parts of bighead atractylodes rhizome, 18 parts of ligusticum wallichii, 18 parts of rhizoma corydalis, 12 parts of poria cocos, 12 parts of cassia twig, 12 parts of honey-fried licorice root, 10 parts of buckeye seeds, 10 parts of apocynum venetum, 10 parts of rhizoma acori graminei and 6 parts of immature bitter orange.

The medicine can be prepared into any conventional oral preparation by adopting a conventional method of a traditional Chinese medicine preparation, in order to enable each component to better exert the drug effect, the honey-fried licorice root in the raw material medicines is preferably subjected to special extraction, and the volatile oil of the honey-fried licorice root, the immature bitter orange and the grassleaf sweelflag rhizome is extracted by steam distillation. These particular processes, however, are not intended to limit the scope of the present invention.

Preferably, the pharmaceutically active ingredient of the present invention is prepared as follows:

a) weighing herba Lycopi, Atractylodis rhizoma, rhizoma Ligustici Chuanxiong, fructus Aurantii Immaturus, rhizoma corydalis, Poria, ramulus Cinnamomi, semen Aesculi, herba Apocyni Veneti, and stone

Rhizoma Acori Calami and radix Glycyrrhizae Preparata.

) Decocting 7 Chinese medicinal materials of rhizoma Atractylodis Macrocephalae, rhizoma Chuanxiong, rhizoma corydalis, Poria, ramulus Cinnamomi, semen Aesculi, and herba Apocyni Veneti in water for 2 times; adding water for the first time until the water level is 3cm higher than the surface of the medicine, and decocting with slow fire for 50 minutes after boiling; adding water for the second time until the water level is 2cm higher than the surface of the medicine, and decocting with slow fire for 30 minutes after boiling; mixing the two decoctions, filtering to obtain filtrate 1,

c) and (3) extracting herba lycopi, immature bitter orange and rhizoma acori graminei in the weight ratio by using water vapor to collect volatile oil for later use. Mixing water decoction of herba Lycopi, fructus Aurantii Immaturus, and rhizoma Acori Graminei (the preparation method of water decoction is the same as step b) with filtrate 1, concentrating into extract with specific gravity of 1.35, adding 90% -95% ethanol for precipitating, recovering ethanol and concentrating, drying at 45 deg.C-50 deg.C to obtain dry extract 1.

) Adding 90-95% ethanol into the honey-fried licorice root according to the weight ratio for reflux extraction, recovering the ethanol from the extracting solution, and drying at 45-50 ℃ to obtain a dry extract 2.

) Mixing the dry extract 1 and the dry extract 2, pulverizing the dry extracts into powder, uniformly mixing the powder and the powder, spraying the volatile oil of herba lycopi, immature bitter orange and rhizoma acori graminei, and uniformly mixing the powder and the volatile oil to prepare the active component of the medicament.

The active components of the medicine of the invention can be added with various conventional auxiliary materials required by preparing different dosage forms, such as disintegrating agent, adhesive, lubricant, and the like. Can be made into any common oral dosage form such as pill, powder, tablet, capsule, oral liquid, etc. by conventional method.

The medicine has the effects of nourishing blood, calming heart, strengthening spleen, tonifying qi, activating blood, removing blood stasis, promoting diuresis, promoting qi circulation and the like, and is used for preventing and treating coronary heart disease and complications thereof.

[ detailed description ] embodiments

The beneficial effects of the drug of the present invention are further illustrated by the following experimental examples. The experimental examples include pharmacological experiments and clinical efficacy observation experiments of the drug of the invention (abbreviated as "Guanxinan", abbreviated as GXA).

[ Experimental example 1 ] treatment effect of the drug of the invention on isoproterenol-induced myocardial ischemia in rats

The large dose of isoproterenol can induce animals to generate myocardial ischemia, the continuous application can generate myocardial infarction-like injury, the changes of electrocardiogram and histopathology are very close to the changes of the naturally occurring acute myocardial infarction of human beings, and the asymptotic property of the ischemic injury and the change of myocardial enzyme are similar to the characteristics of the myocardial infarction of the human beings. Therefore, the experiment adopts isoproterenol to replicate the myocardial ischemia model of rats and observes the influence of GXA on the model.

Material

1.1 animals

Wistar healthy rats, male, with a weight of 180-220 g, were provided by the Experimental animals center of North Hei medical university. 50 patients without abnormality are checked by an electrocardiogram, and are adaptively fed for one week before the experiment.

Instrument for measuring the position of a moving object

XDH-B type electrocardiograph, manufactured by Shanghai medical electronic instruments and factories; a Humalyzer 2000 type semi-automatic biochemical analyzer, produced in germany; TDL-5-A type centrifuge, Shanghai' an pavilion scientific instrument factory; lycra UTC microtome, manufactured by lycra; transmission electron microscope model H-750, manufactured by Hitachi, Inc.

Reagent

Lactate Dehydrogenase (LDH) kit (lot 160122), glutamic-oxaloacetic transaminase (GOT) kit (lot 160215), Creatine Phosphokinase (CPK) kit (lot 040110), superoxide dismutase (SOD) kit (lot 160218), Malondialdehyde (MDA) kit (lot 160125), etc. were purchased from tokyo institute of bioengineering.

Medicine

Guanxinan (GXA) prescription Chinese medicinal decoction pieces are purchased from Shijiazhuang Lerentang pharmaceutical group member company, are certified as genuine products by experts of Chinese medicine academy of Hebei Chinese medicine institute, and meet the requirements of national medicine standards. Compound red sage root dripping pill: specification 27 mg/pellet, manufactured by Tianjin Tianshili pharmaceutical group GmbH, lot number 20161108. Isoproterenol hydrochloride Injection (ISO): the specification is 1mg/2ml, manufactured by Shanghai Hefeng pharmaceuticals Co., Ltd., lot number 20160706.

2 method

2.1 preparation of Experimental drugs

GXA selecting 28g of herba Lycopi, 18g of rhizoma Atractylodis Macrocephalae, 18g of rhizoma Chuanxiong, 18g of rhizoma corydalis, 12g of Poria cocos, 12g of cassia twig, 12g of radix Glycyrrhizae Preparata, 10g of semen Aesculi, 10g of herba Apocyni Veneti, 10g of rhizoma Acori Tatarinowii and 6g of fructus Aurantii Immaturus as daily dosage for adults (70 kg), and converting the dosage for rats according to the dosage and body surface area conversion algorithm of human and animals. The decoction pieces are prepared into dry powder according to the preparation method provided by the instruction, and are added with water to prepare liquid medicine containing crude drugs with the concentration of 0.14g/ml and 0.28g/ml, and the liquid medicine is stored at low temperature for standby.

The compound salvia miltiorrhiza dripping pill liquid medicine: according to the adult dosage (810 mg/day), the dosage of rats is calculated according to the body surface area conversion algorithm of the dosage of human and animals, and the dosage is dissolved into a liquid medicine with the concentration of 1.5mg/ml by warm distillation water for clinical use.

Animal grouping and model replication

50 rats are randomly divided into 5 groups, each group comprises 10 rats, and the groups respectively comprise a blank control group, a model group, a GXA low dose group (1.4 g/d), a GXA high dose group (2.8 g/d) and a positive control group (compound red sage root dripping pill 15 mg/d). After the experiment is started, GXA high and low dose groups and the positive control group are respectively administrated with corresponding drugs according to 10ml/d intragastric administration (the weight of the rat is administrated by 200 g, and the administration amount of the rat is larger than or smaller than 200 g, and the rat is administrated by intragastric administration), and the blank control group and the model group are administrated by infusing distilled water with the same volume for 1 time per day for 7 days continuously. From the 5 th day of the experiment, except for the blank control group, the other groups were injected with Isoproterenol (ISO) injection (5 mg/d) intraperitoneally 1 hour after the gavage administration for 3 days at intervals of 24 hours.

Detection index and method

2.3.1 electrocardiographic examination after anesthetizing a rat by intraperitoneal injection of 20% urethane solution at a weight of 5mg/kg, lying on the back on an operating table, 4 needle electrodes were inserted subcutaneously into the four limbs of the rat at prescribed positions (red-right forelimb, yellow-left forelimb, blue-left hind limb, black-right hind limb), and standard limb II-lead electrocardiography (paper feeding speed 50mm/s, standard voltage 1mv =10 mm) was recorded 10 minutes before and 30 minutes after the first injection of ISO. The changes of electrocardiogram before and after the model making of the rat are compared by self control. The reference reports that the number of positive-reacting animals was counted and analyzed as positive reaction by shifting J point (increase or decrease. gtoreq.0.1 mv), or changing T wave (rise, biphase or inversion), or appearance of Q wave.

Serum LDH, CPK, GOT assays

Rats were sacrificed 2 hours after the last ISO injection, carotid blood was taken, placed in glass tubes, centrifuged for 10 minutes (3000 rpm), and serum was extracted. The activities of serum LDH, CPK and GOT are detected according to the method provided by the kit (colorimetric method for LDH and CPK and Reichner method for GOT).

Observation of myocardial ultrastructure in 2 minutes after killing rat, quickly cutting the same part of cardiac apex of rat, trimming into specimen with size of 1X 3mm, placing into 4% glutaraldehyde solution, storing and fixing for 1 hour at 0-4 deg.C, after washing with phosphate buffer solution, carrying out post-fixing with osmic acid, then washing with phosphate buffer solution, acetone gradient dewatering, soaking, embedding, slicing and other treatments, making into ultrathin slice, double staining with uranium acetate and lead citrate, and observing the ultrastructure of myocardial cell under transmission electron microscope.

Detection of myocardial MDA and SOD

Taking cardiac muscle tissue of the same part of a cardiac apex, washing with normal saline, draining with filter paper, weighing appropriate amount, placing in a homogenizer, adding normal saline, grinding under ice water bath condition to obtain 10% tissue homogenate, and detecting SOD activity and MDA content according to the method provided by the kit (xanthine oxidase method is used for SOD, and thiobarbituric acid method is used for MDA).

Data processing

Chi for counting data²And (5) checking and analyzing. Metrology data is expressed in x ± s, and comparisons between groups were performed using one-way anova with statistical processing using SPSS version 11.5 software.

Results

1 Effect on rat Electrocardiogram

All 10 rats in the model group have positive reaction, which is represented by J point displacement and abnormal T wave, and some rats have Q wave (no Q wave before modeling); the electrocardiograms of the blank control group are all normal, no positive reaction occurs, and the difference of the two groups is obvious (P is less than 0.01), which indicates that the modeling is successful. GXA the number of positive-reacting animals in the high and low dose groups and the positive control group was significantly less than that in the model group (P < 0.05 or P < 0.01). The number of positive-reacting animals in the high dose group was less than that in the low dose group, but not statistically significant (P > 0.05). See attached Table 1.

Effect on rat cardiac myogenases

Compared with a blank control group, the activities of GOT, LDH and CPK of the model group are obviously improved (P is less than 0.01), and the success of molding is indicated. GXA the activities of GOT, LDH and CPK were significantly decreased (P < 0.05 or P < 0.01) in the high and low dose groups and the positive control group compared with the model group. GXA there was no significant difference between the high and low dose groups (P > 0.05). See attached Table 2.

Influence on rat cardiac ultrastructure

And (3) displaying under a transmission electron microscope: the muscle fibers of the blank control group are arranged regularly, the mitochondria are complete, and the ridge is arranged regularly; the arrangement of muscle fibers of the model group is disordered, mitochondria are swelled and even broken, and cristae is dissolved and disappears; GXA the arrangement of muscle fibers in the high-dose group is basically normal, the mitochondria are complete, the cristae occasionally fuses or disappears, and the lesion is slight; GXA the low dose group had mild disorganization of the myofiber arrangement, intact mitochondria, and partial dissolution or disappearance of the cristae; the degree of pathological changes in ultrastructure of the positive control group was similar to that of the low dose group.

Influence on myocardial SOD and MDA of rats

Compared with the blank control group, the SOD activity of the model group is obviously reduced (P is less than 0.01), and the MDA content is obviously increased (P is less than 0.01). GXA compared with the model group, the SOD activity of the high and low dose groups and the positive control group are both increased significantly (P < 0.05 or P < 0.01), and the MDA content is both decreased significantly (P < 0.05 or P < 0.01). GXA there is no significant difference in SOD activity and MDA content between high and low dose groups (P > 0.05). See attached Table 3.

Table 1 The effect of GXA on rats electrocardiogram(n=10)

Grouping	Dosage (g/d)	Number of positive reaction animals	Number of negative animals	Positive rate
					Blank control group	——	0	10	0^**
Model set	——	10	0	100%
					GXA high dose group	2.8	3	7	30%^**
GXA Low dose group	1.4	4	6	40%^*
					Positive control group	0.015	4	6	40%^*

Compared with model group *P＜0.05 **P＜0.01

Table 2 The effect of GXAon LDH，GOT & CPK of rats serum ( x±ｓ)(n=10)

Grouping	Dosage (g/d)	LDH(U/ml)	GOT	CPK(U/ml)
					Blank control group	——	13.76±2.32**	65.36±6.98**	27.12±5.98**
Model set	——	18.58±0.87	86.79±9.12	43.13±11.12
					GXA high dose group	2.8	14.63±1.52**	67.34±12.51**	28.39±9.36**
GXA Low dose group	1.4	14.98±1.45**	71.28±10.96**	33.12±8.57*
					Positive control group	0.015	15.49±1.13**	70.32±9.87**	29.58±7.39**

Compared with model group *P＜0.05 **P＜0.01

Table 3 The effect of GXA on SOD & MDA of rats myocardium ( x±ｓ)(n=10)

Grouping	Dosage (g/d)	SOD(U/mgprot)	MDA(nmol/mgprot)
				Blank control group	——	239.12±63.18**	1.08±0.19**
Model set	——	152.43±21.64	1.69±0.38
				GXA high dose group	2.8	198.12±14.09**	1.11±0.13**
GXA Low dose group	1.4	188.97±28.34*	1.12±0.23**
				Positive control group	0.015	188.19±21,54*	1.25±0.27*

Compared with model group *P＜0.05 **P＜0.01

[ EXPERIMENTAL EXAMPLE 2 ] clinical observation of the drug of the present invention for treating coronary heart disease and its complications

1 case data:

195 out-patient patients were selected; among them, 97 male patients and 98 female patients; 70 patients 70-80 years old, 55 patients 60-70 years old, 35 patients 50-60 years old, 25 patients 40-50 years old, and 10 patients under 40 years old. 195 patients were randomized into treatment groups, control groups.

Case selection criteria:

referring to the establishment standard of the world health organization for coronary heart disease, the following diagnosis standard is established:

(1) acute coronary syndrome, including unstable angina, non-ST elevation myocardial infarction, ST elevation myocardial infarction.

(2) Chronic coronary artery disease, stable angina pectoris, coronary normal angina pectoris, asymptomatic myocardial ischemia, and ischemic heart failure.

The treatment method comprises the following steps:

the patients in the treatment group applied the traditional Chinese medicine preparation of the invention in the embodiment 1 to take orally, 2 capsules each time, 1 time each in the morning, the middle and the evening. A treatment course is 7 days, and 10 treatment courses are continuously taken. The control group of patients take the dripping pill 10 granules each time 1 times respectively in the morning, in the middle of the day and at night strictly according to the dosage standard of the medicine. A treatment course is 7 days, and 10 treatment courses are continuously taken.

Standard of therapeutic effect

And (3) curing: the electrocardiogram segment is recovered to be normal, the coronary heart disease and the clinical symptoms such as typical chest pain, precordial discomfort, palpitation or hypodynamia, heart failure and the like caused by the coronary heart disease disappear, the body resistance is increased, and the heart function is recovered to be normal.

Improvement: the electrocardiogram wave returns to normal or low level from inversion, the symptoms are relieved, the body resistance is increased, and the heart function is improved.

And (4) invalidation: the electrocardiogram has no obvious change and no obvious change of symptoms.

	Number of examples	Cure of disease	Improvement of life	Invalidation	Cure rate	Total effective rate
							Treatment group	98	51	44	3	52.04%	96.94%
Control group	97	38	42	17	39.18%	82.47%

[ classic cases ]

Mr. Chua, 53 years old, precordial pain nearly half a year, often feeling chest distress, shortness of breath, aggravation after activity, occasionally nausea and vomiting, often feeling precordial pain, and diagnosed by a doctor as coronary heart disease. The capsules of the embodiment are taken orally 3 times a day after meals in the morning, at noon and at night, 10 capsules are taken each time, and 10 days are a treatment course. After about 2 months, angina pectoris has not been attacked, and after taking 10 courses of treatment, the angina pectoris returns to normal, and then the angina pectoris is followed for 2 years without recurrence.

Liu female, 73 years old, suffered from recurrent chest pain for 3 years, palpitation, frequent dyspnea, inappetence, insomnia, dreaminess, nausea and vomiting when the pain is severe, and western medicine diagnosed as angina pectoris. The granules of the examples were taken 3 times a day in the morning, at noon and at night, 10g each time. The treatment course is 10 days, the symptoms are relieved after 3 treatment courses, the symptoms completely disappear after 10 treatment courses, the administration is continued for 5 treatment courses, and the symptoms are not relapsed after 2 years of follow-up.

Mr. Pan, 56 years old, suffer from recurrent angina pectoris for 2 years, the electrocardiogram shows that T wave is inverted, myocardial ischemia, it is not good enough to administrate western medicine therapeutic effect, tablet treatment of the embodiment of self-administration, take orally after breakfast, lunch, supper every day, 10 tablets each time, 10 days are a course of treatment, the symptom is relieved after 5 courses of treatment, the pain disappears after 10 courses of treatment, the electrocardiogram is obviously improved, continue taking 5 courses of treatment and consolidate the curative effect, there is no recurrence 2 years at the time of diagnosis.

Korean women, 45 years old, paroxysmal tachycardia of more than 3 years, cardiac hypertrophy and heart failure, ischemic coronary heart disease diagnosed by Western medicine, the granule is taken for treatment, the granule is taken orally after breakfast, lunch and supper every day, 10g of the granule is taken every time, 10 days are taken as a treatment course, symptoms are relieved after 5 treatment courses, pain disappears after 10 treatment courses, electrocardiogram is obviously improved, the curative effect is consolidated after continuously taking 5 treatment courses, and no relapse occurs after 2 following diagnosis.

The traditional Chinese medicine is old and born 72 years old, and is diagnosed to suffer from coronary heart disease 2 years ago, symptoms such as palpitation, shortness of breath, dysphoria, angina pectoris and the like appear after slight exercise, various medicines are used for treatment once, obvious improvement is not seen, the tablet treatment in the embodiment is taken, the tablet is taken orally after breakfast, lunch and supper every day, 10 tablets are taken each time, 10 days are taken as a treatment course, the symptoms are relieved after 3 treatment courses, the pain disappears after 5 treatment courses, the electrocardiogram is obviously improved, the curative effect is consolidated after 5 treatment courses of continuous taking, and no relapse occurs after 2 years of follow-up diagnosis.

The Wang lady, 43 years old, for more than 1 year, feels chest distress with hot flashes and night sweats, sometimes with precordial stabbing pain or chest pain penetrating the back, and is diagnosed as myocardial ischemia. The western medicine treatment has no obvious effect. The oral liquid of the embodiment is taken for treatment, the oral liquid is taken after breakfast, lunch and supper every day, 10ml is taken each time, 10 days is one treatment course, symptoms are relieved after 3 treatment courses, chest distress and pain disappear after 5 treatment courses, the curative effect is consolidated after 8 treatment courses of continuous taking, and no relapse occurs after 2 years of follow-up diagnosis.

Mr. Shi, 65 years old, used to diet rich, sweet and thick taste, smoking and drinking in recent 20 years, suffered from obesity, hyperlipidemia and hypertension for more than ten years. Chest distress, palpitation, short breath, insomnia and hypodynamia in recent 2 years, and myocardial infarction is diagnosed. The symptoms of the western medicines are relieved but cannot be maintained. The oral liquid of the embodiment is taken for treatment, the oral liquid is taken after breakfast, lunch and supper every day, 10ml is taken every time, 10 days is one treatment course, symptoms are relieved after 2 treatment courses, the symptoms disappear after 8 treatment courses, the treatment effect is consolidated after 8 treatment courses of administration, a patient with a petition pays attention to diet daily life, the patient is diagnosed with the disease for 2 years without relapse, and the blood pressure and the blood fat are recovered to be normal.

[ example 1 ] preparation of pharmaceutical capsules of the present invention

a) Weighing 28g of herba lycopi, 18g of rhizoma atractylodis macrocephalae, 18g of ligusticum wallichii, 18g of rhizoma corydalis, 12g of poria cocos, 12g of cassia twig, 12g of radix glycyrrhizae preparata, 10g of semen aesculi, 10g of apocynum venetum, 10g of rhizoma acori graminei and 6g of immature bitter orange for later use.

c) and (3) extracting herba lycopi, immature bitter orange and rhizoma acori graminei in the weight ratio by using water vapor to collect volatile oil for later use. Mixing water decoction of herba Lycopi, fructus Aurantii Immaturus, and rhizoma Acori Graminei (the water decoction is obtained by the same method as step b) and filtrate 1, concentrating into extract with specific gravity of 1.35, precipitating with 90-95% ethanol, recovering ethanol, concentrating, drying at 45-50 deg.C to obtain dry extract 1.

) Mixing the dry extract 1 and the dry extract 2, pulverizing the dry extracts into powder, mixing the powder uniformly, pulverizing the powder into fine powder, spraying the volatile oil of herba lycopi, immature bitter orange and rhizoma acori graminei, mixing the powder uniformly, and filling the mixture into gelatin hard capsules, wherein each capsule contains about 1 g of the compound active ingredient.

[ example 2 ] preparation of pharmaceutical granules of the present invention

a) Weighing raw materials of 32g of herba lycopi, 22g of rhizoma atractylodis macrocephalae, 22g of ligusticum wallichii, 18g of rhizoma corydalis, 13g of poria cocos, 12g of cassia twig, 12g of radix glycyrrhizae preparata, 12g of semen aesculi, 10g of apocynum venetum, 12g of rhizoma acori graminei and 8g of immature bitter orange for later use.

c) and (3) extracting herba lycopi, immature bitter orange and rhizoma acori graminei in the weight ratio by using water vapor to collect volatile oil for later use. Mixing water decoction of herba Lycopi, fructus Aurantii Immaturus, and rhizoma Acori Graminei (the water decoction is obtained in the same step b) with the filtrate 1, concentrating to obtain extract with specific gravity of 1.35, precipitating with 90-95% ethanol, recovering ethanol, concentrating, and drying at 45-50 deg.C to obtain dry extract 1.

) Mixing dry extract 1 and dry extract 2, pulverizing into powder, mixing, pulverizing into fine powder, spraying herba Lycopi, fructus Aurantii Immaturus, and rhizoma Acori Graminei volatile oil, mixing, adding ethanol as binder, adding starch as filler, and making into granule.

[ example 3 ] preparation of tablets of the drug of the present invention

a) Weighing 28g of herba lycopi, 22g of rhizoma atractylodis macrocephalae, 22g of ligusticum wallichii, 20g of rhizoma corydalis, 16g of poria cocos, 16g of cassia twig, 16g of radix glycyrrhizae preparata, 10g of semen aesculi, 10g of apocynum venetum, 10g of rhizoma acori graminei and 6g of immature bitter orange for later use.

) Mixing the dry extract 1 and the dry extract 2, pulverizing the dry extracts into powder, mixing the powder uniformly, pulverizing the powder into fine powder, spraying the volatile oil of herba lycopi, immature bitter orange and rhizoma acori graminei, mixing the powder uniformly, and pressing the mixture into tablets, wherein each tablet contains 1 g of the compound active ingredient.

[ example 4 ] preparation of the pharmaceutical oral liquid of the present invention

a) Weighing raw materials of 32g of herba lycopi, 22g of rhizoma atractylodis macrocephalae, 22g of ligusticum wallichii, 22g of rhizoma corydalis, 16g of poria cocos, 16g of cassia twig, 16g of honey-fried licorice root, 14g of buckeye, 14g of apocynum venetum, 14g of rhizoma acori graminei and 8g of immature bitter orange for later use.

) Mixing dry extract 1 and dry extract 2, pulverizing into powder, mixing, and pulverizing into fine powder.

) Adding ethanol into the fine powder to make ethanol content reach 55%, standing for 24 hr, filtering, recovering ethanol, concentrating to obtain soft extract with relative density of 1.26-1.30 (60 deg.C), adding herba Lycopi prepared in step c), fructus Aurantii Immaturus, rhizoma Acori Graminei volatile oil, sodium benzoate 2g, sucrose 50g, and distilled water (the addition amount of distilled water is 10g per 10ml of medicinal liquid), filtering, sterilizing, and bottling.

[ example 5 ] preparation of pharmaceutical pellets of the present invention

a) Weighing 24g of herba lycopi, 14g of rhizoma atractylodis macrocephalae, 14g of ligusticum wallichii, 14g of rhizoma corydalis, 8g of poria cocos, 8g of cassia twig, 8g of radix glycyrrhizae preparata, 6g of semen aesculi, 6g of apocynum venetum, 6g of rhizoma acori graminei and 4g of immature bitter orange for later use.

Decocting 7 Chinese medicinal materials of rhizoma Atractylodis Macrocephalae, rhizoma Chuanxiong, rhizoma corydalis, Poria, ramulus Cinnamomi, semen Aesculi, and herba Apocyni Veneti in water for 2 times; adding water for the first time until the water level is 3cm higher than the surface of the medicine, and decocting with slow fire for 50 minutes after boiling; adding water for the second time until the water level is 2cm higher than the surface of the medicine, and decocting with slow fire for 30 minutes after boiling; mixing the two decoctions, filtering to obtain filtrate 1,

c) and (3) extracting herba lycopi, immature bitter orange and rhizoma acori graminei in the weight ratio by using water vapor to collect volatile oil for later use. Mixing the water decoction of herba Lycopi, fructus Aurantii Immaturus, and rhizoma Acori Graminei with the filtrate 1, concentrating to obtain extract with specific gravity of 1.35, precipitating with 90-95% ethanol, recovering ethanol, concentrating, and drying at 45-50 deg.C to obtain dry extract 1.

) Mixing dry extract 1 and dry extract 2, pulverizing into powder, mixing, pulverizing into fine powder, spraying herba Lycopi, fructus Aurantii Immaturus, and rhizoma Acori Graminei volatile oil, mixing, adding refined honey 30-50g per 100g of powder, making into pill, drying, polishing or coating with sugar. Each pill contains 10g of compound active ingredients.

Claims

1. The traditional Chinese medicine composition for preventing and treating coronary heart disease is characterized by comprising the following raw material medicines in parts by weight:

25-32 parts of herba lycopi, 14-22 parts of bighead atractylodes rhizome, 14-22 parts of ligusticum wallichii, 14-22 parts of rhizoma corydalis

8-16 parts of poria cocos, 8-16 parts of cassia twig, 8-16 parts of honey-fried licorice root, 6-14 parts of buckeye seed

6-14 parts of apocynum venetum, 6-14 parts of rhizoma acori graminei and 4-8 parts of immature bitter orange.

2. The traditional Chinese medicine composition according to claim 1, which is characterized by comprising the following raw material medicines in parts by weight:

26-30 parts of herba lycopi, 16-20 parts of bighead atractylodes rhizome, 16-20 parts of ligusticum wallichii and 16-20 parts of rhizoma corydalis

10-14 parts of poria cocos, 10-14 parts of cassia twig, 10-14 parts of honey-fried licorice root, 8-12 parts of buckeye

8-12 parts of apocynum venetum, 8-12 parts of rhizoma acori graminei and 5-7 parts of immature bitter orange.

3. The traditional Chinese medicine composition according to claim 1, which is characterized by comprising the following raw material medicines in parts by weight:

herba lycopi 28 parts, bighead atractylodes rhizome 18 parts, ligusticum wallichii 18 parts, corydalis tuber 18 parts

12 parts of poria cocos, 12 parts of cassia twig, 12 parts of honey-fried licorice root, 12 parts of buckeye seed and 10 parts of buckeye

10 parts of apocynum venetum, 10 parts of rhizoma acori graminei and 6 parts of immature bitter orange.

4. The Chinese medicinal composition according to claim 1, 2 or 3, which is prepared by a method comprising the steps of:

a) weighing the raw materials of herba lycopi, rhizoma atractylodis macrocephalae, rhizoma ligustici wallichii, immature bitter orange, rhizoma corydalis, poria cocos, cassia twig, semen aesculi, apocynum venetum, rhizoma acori graminei and radix glycyrrhizae preparata for later use;

b) decocting 7 Chinese medicinal materials of rhizoma Atractylodis Macrocephalae, rhizoma Chuanxiong, rhizoma corydalis, Poria, ramulus Cinnamomi, semen Aesculi, and herba Apocyni Veneti in water for 2 times; adding water for the first time until the water level is 3cm above the medicine surface, boiling, and decocting with slow fire for 50 minutes; adding water 2cm below the surface of the medicine for the second time, and decocting with slow fire for 30 minutes after boiling; mixing the two decoctions, and filtering to obtain filtrate 1;

c) collecting volatile oil from herba Lycopi, fructus Aurantii Immaturus, and rhizoma Acori Graminei at the above weight ratio by steam extraction method; mixing water decoction of herba Lycopi, fructus Aurantii Immaturus, and rhizoma Acori Graminei with the filtrate 1, concentrating into extract with specific gravity of 1.35, precipitating with 90-95% ethanol, recovering ethanol, concentrating, and drying at 45-50 deg.C to obtain dry extract 1;

d) adding 90-95% ethanol into the honey-fried licorice root according to the weight ratio for reflux extraction, recovering the ethanol from the extracting solution, and drying at 45-50 ℃ to obtain a dry extract 2;

e) mixing dry extract 1 and dry extract 2, pulverizing into powder, mixing, pulverizing into fine powder, spraying herba Lycopi, fructus Aurantii Immaturus, and rhizoma Acori Graminei volatile oil, and stirring.

5. The Chinese medicinal composition of claim 4, wherein the active ingredient prepared in step e) is combined with common adjuvants to make into pill, tablet, granule, capsule, and oral liquid.

6. The use of the Chinese medicinal composition according to any one of claims 1 to 3 in the preparation of a medicament for the prevention and treatment of coronary heart disease and its complications.